Efpeglenatide

N/A

Report date: 2024/08/13 11:19:41

Base Information

Drug NameEfpeglenatide
Drug Alias NameLanglenatideLAPS-exendin 4 analogueLAPSCA-Exendin4LAPS-Exendin4LAPS-Exd4 +[9] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2Diabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaUnited States +[31] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHanmi Pharmaceutical Co Ltd
Inactive CompaniesSanofiSanofi (China) Investment Co Ltd
Active IndicationsObesityDiabetes Mellitus, Type 2
Inactive IndicationsDiabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A